How should hyperkalemia be managed in a patient with chronic kidney disease?

Management of Hyperkalemia in Chronic Kidney Disease

In CKD patients with hyperkalemia, prioritize maintaining RAAS inhibitor therapy while actively treating the elevated potassium through dietary modification, addressing reversible causes, and using newer potassium binders (patiromer or sodium zirconium cyclosilicate) rather than discontinuing cardioprotective medications. 1

Acute vs. Chronic Hyperkalemia: Different Strategies

Acute Hyperkalemia (K+ >5.5 mmol/L with ECG changes or symptoms)

For life-threatening presentations, implement immediate stabilization:

• IV calcium gluconate (10 mL of 10%) - stabilizes cardiac membrane within 1-3 minutes, repeat if no effect in 5-10 minutes 2
• IV insulin (10 units) + glucose (50 mL dextrose) - shifts potassium intracellularly within 30 minutes 2
• Nebulized salbutamol (20 mg in 4 mL) - redistributes potassium but has short duration (2-4 hours) 2
• IV sodium bicarbonate - only in patients with concurrent metabolic acidosis 2
• Hemodialysis - for resistant cases, especially with oliguria or ESRD 2

Critical caveat: ECG findings are highly variable and not sensitive predictors of hyperkalemia severity - do not rely solely on ECG to guide treatment urgency 2

Chronic Hyperkalemia Management (K+ 5.0-5.5 mmol/L or recurrent)

The fundamental principle is never discontinue RAAS inhibitors solely for hyperkalemia - discontinuation increases mortality and cardiovascular events 2. Instead:

Step-by-Step Management Algorithm

1. Verify True Hyperkalemia

• Rule out pseudohyperkalemia from hemolysis, fist clenching during phlebotomy, or delayed sample processing 2
• Plasma K+ runs 0.1-0.4 mmol/L lower than serum 2
• Repeat measurement before making therapeutic changes

2. Identify and Remove Reversible Causes

• Review medications: NSAIDs, potassium-sparing diuretics, heparin, trimethoprim 2
• Assess for metabolic acidosis and correct with bicarbonate 1
• Evaluate volume status - optimize diuretic therapy in hypervolemic patients 2

3. Dietary Modification

• Address potassium additives and processed foods before restricting fruits and vegetables 3
• Avoid potassium-containing salt substitutes and herbal remedies 4
• Target dietary potassium restriction only if eGFR <30 mL/min 4

Important nuance: Recent KDIGO guidance questions rigid low-potassium diets, as evidence linking dietary intake to serum levels is limited and potassium-rich diets have cardiovascular benefits 2. Prioritize processed food reduction over whole food restriction 3.

4. Optimize RAAS Inhibitor Therapy - Do Not Discontinue

For patients requiring RAAS inhibitors (which is most CKD patients):

• Continue maximum tolerated RAAS inhibitor dose 2
• If K+ rises to 5.5 mmol/L, add potassium binder rather than reducing RAAS inhibitor 1
• Only temporarily hold RAAS inhibitors during acute severe hyperkalemia, then reinitiate after resolution 2

5. Add Nonsteroidal MRA (Finerenone) When Appropriate

For patients with type 2 diabetes, eGFR >25 mL/min/1.73 m², and albuminuria >30 mg/g despite maximum RAAS inhibition 1:

Finerenone dosing protocol 1:

• K+ ≤4.8 mmol/L: Initiate 10 mg daily (eGFR 25-59) or 20 mg daily (eGFR ≥60)
• K+ 4.9-5.5 mmol/L: Continue current dose, monitor K+ every 4 months
• K+ >5.5 mmol/L: Hold finerenone, adjust diet/medications, recheck K+, restart at 10 mg when K+ ≤5.0 mmol/L

Monitor potassium at 1 month after initiation, then every 4 months 1

6. Potassium Binders for Chronic Management

Newer agents (preferred) 1, 5, 6:

• Patiromer or sodium zirconium cyclosilicate (SZC) - proven efficacy in randomized trials for CKD patients on RAAS inhibitors
• Enable continuation of cardioprotective medications
• More effective and better tolerated than older resins

Older agents 6:

• Sodium polystyrene sulfonate (SPS) - risk of hypervolemia from sodium exchange
• Calcium polystyrene sulfonate (CPS) - avoids hypervolemia, used in Asia, limited trial data

Real-world evidence: Newer binders show no significant difference in recurrence rates compared to resins, but allow sustained RAAS inhibitor use 5

7. Monitoring Strategy

Individualize based on risk factors 2:

• High-risk patients (CKD G4-5, diabetes, heart failure, on RAAS inhibitors): Check K+ 7-10 days after starting/increasing RAAS inhibitor dose 2
• Baseline eGFR <30 mL/min: Higher recurrence risk (49% vs 39%) 5
• Stable patients: Every 4 months if on MRA 1

Key Clinical Pitfalls to Avoid

1. Do not discontinue RAAS inhibitors for mild hyperkalemia - this increases mortality 2
2. Do not rely on ECG alone - findings are variable and insensitive 2
3. Do not assume dietary restriction alone will suffice - address medications and consider binders 4
4. Do not ignore the rate of K+ rise - rapid increases are more dangerous than chronic elevation 2
5. Recognize CKD patients tolerate higher K+ levels - optimal range in CKD G4-5 is 3.3-5.5 mmol/L vs 3.5-5.0 in early CKD 2

Special Considerations for SGLT2 Inhibitors

Continue SGLT2 inhibitors even if eGFR falls below 20 mL/min/1.73 m² unless not tolerated 1. These agents provide cardiovascular and renal protection and can be combined with RAAS inhibitors and MRAs 1.

Recurrent hyperkalemia remains common (44% in real-world practice) and associates with faster eGFR decline, though causality is unclear 5. The integration of potassium binders into therapeutic strategies allows optimization of cardioprotective medications while managing electrolyte disturbances.